Human Monocytotropic Ehrlichiosis, Missouri by Olano, Juan P. et al.
To determine the incidence, clinical and laboratory
characteristics, and utility of molecular diagnosis of human
monocytotropic ehrlichiosis (HME) in the primary care set-
ting, we conducted a prospective study in an outpatient pri-
mary care clinic in Cape Girardeau, Missouri. One hundred
and two patients with a history of fever for 3 days
(>37.7°C), tick bite or exposure, and no other infectious dis-
ease diagnosis were enrolled between March 1997 and
December 1999. HME was diagnosed in 29 patients by
indirect immunofluorescent antibody assay and poly-
merase chain reaction (PCR). Clinical and laboratory man-
ifestations included fever (100%), headache (72%), myal-
gia or arthralgia (69%), chills (45%), weakness (38%), nau-
sea (38%), leukopenia (60%), thrombocytopenia (56%),
and elevated aspartate aminotransferase level (52%).
Hospitalization occurred in 41% of case-patients. PCR sen-
sitivity was 56%; specificity, 100%. HME is a prevalent,
potentially severe disease in southeastern Missouri that
often requires hospitalization. Because clinical presentation
of HME is nonspecific, PCR is useful in the diagnosis of
acute HME.  
E
hrlichioses were recognized as causing human infec-
tious diseases relatively recently. Ehrlichiae, oblig-
ately-intracellular gram-negative bacteria, have evolved in
close association with a vector arthropod and a zoonotic
host and have been traditionally recognized as veterinary
pathogens (1–4). In the United States, the first human case
of ehrlichiosis was reported in 1987 (4). In 1991, the agent
was isolated and recognized as a novel pathogen, Ehrlichia
chaffeensis (5). By 1997, 742 cases in 47 states had been
reported to the Centers for Disease Control and
Prevention, most likely an underestimate of the true inci-
dence (6). Passive reporting of cases has yielded the con-
cept that even in the states with the most cases the inci-
dence is low (e.g., 0.5 cases/100,000 persons in Arkansas).
The clinical spectrum of human monocytotropic ehrlichio-
sis (HME) ranges from mild to a life-threatening multisys-
tem disease (7–11) with a case-fatality rate of 2% to 3%
and a duration of illness in the absence of antiehrlichial
treatment averaging 3 weeks. The clinical manifestations
are neither sensitive nor specific for the diagnosis of HME.
Sequelae include asthenia that can continue months after
recovery and an ill-defined immunosuppression that pre-
disposes the patient to opportunistic infections.
Conversely, E. chaffeensis can cause overwhelming infec-
tion in patients with AIDS or other immunosuppressive
conditions (12–14). 
The exploding population of the natural reservoir of E.
chaffeensis,  white-tailed deer, and the expansion of the
range and population of the vector tick Amblyomma amer-
icanum are important ecologic factors in the continuing
emergence of HME (15–19). Other tick-borne human
granulocytotropic infections are caused by Anaplasma
phagocytophilum and E. ewingii. 
Although HME was described more than a decade ago,
prospective studies are scarce (8,20–22). The present
investigation describes the first office-based, prospective
study of HME in the primary care setting, an investigation
over a period of 3 years in southeast Missouri. 
Materials and Methods
Epidemiologic and Clinical Data 
The study area included Cape Girardeau and surround-
ing counties in southeast Missouri and southwestern
Illinois. Approximately 100,000 persons were covered by
the health services offered by the medical community.
Patients were enrolled from March 1997 through
December 1999. The clinical definition of a potential
HME case-patient was a patient who had had fever
(>37.7°C) for >3 days, possible tick bite or other tick
exposure, and no other infectious disease diagnosis estab-
lished. The patients were given two questionnaires, one
during the acute phase of the disease and the second dur-
ing the convalescent phase when the diagnosis of HME
was confirmed by appropriate laboratory studies. A third
questionnaire was given to the primary care provider. The
information requested included the following: age, gender,
occupation, tick exposure/bites, clinical signs and symp-
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‡Focus Technologies, Cypress, California, USAtoms, duration of symptoms, occurrence and duration of
hospitalization, antibiotic treatment, days of treatment
until resolution of fever, and laboratory data. The protocol
study was approved by the Institutional Review Board of
the University of Texas Medical Branch.
Statistical Analysis 
All patient information and laboratory results were
entered into Microsoft Excel worksheets (Microsoft Corp.,
Redmond, WA). Data were analyzed by using Sigma Stat
Version 2.03 (SPSS Inc., Chicago, IL). 
Laboratory Case Definition Criteria 
Definite and Probable HME Cases
A definite HME case was defined as follows: Patients
who met the clinical definition and had one of the follow-
ing conditions: a) serologic immunoglobulin (Ig) G rise
from <1:64 to >1:64 with a positive polymerase chain
reaction (PCR) result, or b) IgG seroconversion (fourfold
rise) to >1:128 without positive PCR or c) positive PCR
results in two separate laboratories or for at least two tar-
get genes, or d) single serum Ig G titer of >1:256, or e)
positive culture for E. chaffeensis. 
A probable case of HME was defined as follows:
Patients who met the clinical definition and had a) single
IgG titers of 1:64 or 1:128, or b) positive PCR results in
one laboratory for only one target gene.
Processing of Blood Samples 
The samples were collected in EDTA-containing tubes
and shipped in wet ice overnight to the University of Texas
Medical Branch in Galveston. The blood elements were
separated by differential gradient centrifugation with
Ficoll-Hypaque. The mononuclear band was harvested,
washed twice in phosphate-buffered saline (PBS), and
resuspended in 2 mL of PBS; 500 µL was then added to
DH82, THP-1, and HL-60 cell cultures. The remaining 500
µL was saved for PCR analysis. Serum samples were
received separately in red-topped tubes and kept at –20°C
until antibody analysis was performed. 
Indirect Immunofluorescent Antibody Assays (IFA)
Serum specimens were screened at 1:64 dilution,
according to a previously published protocol (23). Positive
serum specimens were diluted serially in twofold incre-
ments to 1:4,096. The highest dilution with a 1+ intensity
of fluorescent staining was considered the end-point titer.
HL60 cells infected with A. phagocytophilum (Webster
strain) were also used for IFA testing for human granulo-
cytic anaplasmosis (HGA). The cut-off values for HGA
testing were set at 1:80, and the samples were serially
diluted to 1:1280. 
Preparation of DNA
DNA was extracted from the harvested mononuclear
band by using the IsoQuick Extraction kit (ORCA
Research, Bothell, WA) during the first year of the study
and with the QIAgen DNA extraction kit (QIAgen, Santa
Clarita, CA), according to the manufacturer’s instructions,
during the remaining 2 years. 
PCR Reactions
16S rRNA Subunit Gene 
For the first-stage amplification of this gene, a 100-µL
reaction mixture containing 10 µL of DNA template, 75
µL of sterile H2O, 10 µL of 10X PCR buffer (Boehringer
Manheim, Indianapolis, IN), 1 µL of primers ECB and
ECC (Table 1) at a final concentration of 1 µM each, 2 µL
of deoxynucleotide triphosphates (final concentration,
200  µM), and 1 µL of  Taq polymerase (Boehringer
Manheim, Indianapolis, IN; final concentration 2.5 U).
For nested PCR, 1 µL of each first-stage amplification
reaction was amplified in a second 100-µL reaction tube
after careful manipulation of the specimens in an
AirClean 600 Workstation (AirClean Systems, Raleigh,
NC) and aspiration of the PCR mixture with cotton-filled
tips. The conditions were the same except for the use of
species-specific primers for E. chaffeensis, HE1 and HE3
(Table 1).
120-kDa Protein Gene 
The first-stage amplification reactions contained the
same reagents as described above with the exception of E.
chaffeensis species-specific primers for the 120-kDa pro-
tein gene, PXCF3 and PXAR4. One microliter was then
amplified with nested primers for the 120-kDa protein
gene with primers PXCF3b and PXAR5 (Table 1).
nad A Gene 
The first-stage amplification was done under the same
conditions as described for the other genes with primers
ECHNADA1 and PXCR6. One microliter was then ampli-
fied in a second 100-µL-reaction tube with nested primers
specific for the nad A gene of E. chaffeensis NADPCR and
PXCR7 (Table 1).
16S rRNA gene for HGA
The first-stage amplification reactions contained the
same reagents as described above with the exception of the
universal eubacterial primers for the 16S rRNA subunit
gene, PC5 and Pomod. One microliter was then amplified
with nested primers specific for A. phagocytophilum,
GE9f, and GE10r (Table 1).
All reactions were performed in a PowerBlock II
System (Ericomp Inc., San Diego, CA). The PCR products
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40 min in a 1.5% agarose gel and then stained with ethi-
dium bromide. The gel was then examined under ultravio-
let light. 
Sequence Analysis 
The PCR products were purified by QIAquick
(QIAgen, Santa Clarita, CA). The nucleotide sequence was
then determined by the dideoxynucleotide method of cycle
sequencing with Taq polymerase (ABI Prism 377 DNA
sequencer, Perkin-Elmer Corp., Foster City, CA). The
sequencing reaction was carried out for each strand of
DNA to avoid possible errors of incorporation of
nucleotides by Taq polymerase. The sequences were ana-
lyzed by Genetics Computer Group, Wisconsin Package
software and by Lasergene software (DNA Star, Inc.,
Madison, WI).
Cultivation 
Ehrlichial isolation was attempted by adding DH82,
THP-1, and HL-60 cell lines as described above. The
flasks were fed every 3–4 days as needed and kept for up
to 60 days at 37°C and 5% CO2. Samples of the cell mono-
layers or suspensions were stained with DiffQuik weekly
and evaluated for the presence of intracellular morulae. At
the end of 60 days, and before discarding the flasks, DNA
was extracted from the cell monolayers or flasks as
described above. PCR was then performed with 16S rRNA
ehrlichial primers that were used for the first-stage reac-
tions described above. 
Results
Demographic Findings
A total of 102 patients met the clinical definition crite-
ria and were enrolled in the study during the 3-year period
(three full tick seasons). HME was diagnosed in 29
patients on the basis of the defined criteria (case-patients,
Table 2). Twenty-five of these cases were considered defi-
nite, and four were considered probable. Six cases were
diagnosed in 1997, 14 in 1998, and nine in 1999.
Seronegative patients from whom convalescent-phase
serum samples were not obtained were excluded from the
study as well as those who did not answer the question-
naires (53 patients). Of the 49 case-patients that were
included in the final analysis, paired-serum samples were
available in 33 cases. Twenty of these case-patients did not
show seroconversion and therefore comprised the control
group (noncase-patients). Twenty-one case-patients (72%)
were male and eight case-patients (28%) were female. The
age of the patients ranged from 15 to 78 years (mean: 48.2
years).  The mean age for men was 48.8 years and for
women, 46.1 years. Ages ranged from 15 to 70 years for
men and 22 to 78 years for women. Twenty-three case-
patients (79%) lived in a southeast Missouri county (Cape
Girardeau, Bollinger, Scott, Stoddard, Phelps, and Perry)
and six case-patients (21%) lived in a southwestern Illinois
county (Union, Jackson and Johnson) (Figure). A tick bite
was documented in 21 case-patients (72%), and tick expo-
sure without a tick bite in 8 case-patients (28%). For all
case-patients, tick attachment ranged from 24 to 72 hours,
except for one case-patient who experienced tick attach-
ment for 12 hours. The incubation period from observed
tick bite until onset of illness ranged from 1 to 4 weeks. All
cases occurred between April and mid-August. Two cases
(7%) occurred in the month of August, five cases (17%) in
May, three cases (10%) in both June and April, and 16
(56%) in July. 
Clinical and Laboratory Findings 
A total of 29 cases were diagnosed with HME by IFA,
PCR, or both. The clinical signs and symptoms associated
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Table 1. List of PCR primers used in this study for amplification of ehrlichial DNA sequences from blood specimens, Cape Girardeau, 
Missouri, 1997–1999 
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a Temperature sequence: Denaturing, annealing and synthesis. Time given in seconds. All polymerase chain reactions (PCR) were performed for 35 cycles. included fever, headache, chills, weakness, nausea, vomit-
ing, diarrhea, abdominal pain, dizziness, dyspnea, cough,
sore throat, stiff neck and cutaneous rash (Table 3). Fever
ranged from 37.9°C to 40.6°C (mean ± SD: 39.4°C ± 0.8).
The most frequent symptoms besides fever were headache,
myalgia or arthralgia, chills, weakness, and nausea.
Coexisting conditions were found in three patients and
included inflammatory bowel disease, adult onset diabetes
mellitus, and coronary artery disease, status post coronary
artery bypass grafting.
Hemoglobin values in all patients ranged from 102 to
169 gm/L (mean ± SD: 136 ±1.7 gm/L). Leukopenia
(defined as leukocyte count [WBC] <4.5 cells x 109/L) was
present in 15 (60%). Of 25 cases in which WBC was ana-
lyzed, the overall range was from 1.2 to 10.0 x 109 cells/L
(mean ± SD: 4.6 ± 2.3 x 109 cells/L). Of 23 patients in
whom platelet counts were analyzed, the overall range was
from 36 to 397 x 109 cells /L(mean ± SD: 153.3 ± 95 x 109
cells/L). Both thrombocytopenia and leukopenia were
present in 11 patients (48%). Thrombocytopenia was
observed in 13 (57%). Serum aspartate aminotransferase
(AST) levels were determined in 21 patients and ranged
from 18 to 538 U/L (mean ± SD: 124.1 ± 146.9 U/L). AST
levels were elevated in 11 patients (52%). Serial blood cell
counts were available in six patients, and all showed WBC
returning to normal values from 7 to 21 days after the ill-
ness started. Lymphopenia was usually seen during the
acute phase of the disease (both relative and absolute) and
was replaced by relative and then absolute lymphocytosis,
beginning at day 9 and occurring up until day 21 in some
cases. 
Altogether, 26 case-patients (90%) had serum antibod-
ies detected by IFA. The three case-patients that were IFA
negative were positive by PCR, and no convalescent-phase
sample could be obtained from these patients. In fact,
acute- and convalescent-phase samples were obtained in
13 patients from the case-patient group. Seroconversion
(defined as a fourfold rise in end-point titers in acute- and
convalescent-phase samples) was demonstrated in seven
case-patients. The remaining case-patients, whose condi-
tion was diagnosed by IFA, had elevated titers in the acute-
phase sample, and the titers rose slightly or remained sta-
ble in the convalescent-phase sample (Table 2). The geo-
metric mean titer in the acute-phase samples was 512 and
633.7 in the convalescent-phase samples. The interval
between acute- and convalescent-phase serum samples
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Table 2. Selected epidemiologic and laboratory results for 29 patients with human monocytotropic ehrlichiosis (HME). Cape Girardeau, 
1997–1999 





convalescent  WBC x 10
9/L  Platelets x 10
9/L 
1  44  M  1999  +  1:512  1:1024  1.9  90 
2  42  M  1999  +  1:256  1:512  3.5  114 
3  63  F  1999  –  1:1024  1:2048  6.4  83 
4  53  M  1999  +  Neg  1:512  4.5  180 
5  77  F  1999  –  1:1024  NA  3.5  44 
6  43  M  1999  +  1:512  NA  1.9  89 
7  48  M  1999  +  1:128  1:2048  4.0  NA 
8  30  M  1999  –  1:1024  NA  NA  NA 
9  28  F  1999  +  1:512  NA  5.4  NA 
10  22  F  1998  +  Neg  1:128  2.1  142 
11  59  M  1998  +  Neg  1:256  8.8  229 
12  67  M  1998  +  Neg  1:512  4.2  36 
13  78  F  1998  +  Neg  NA  NA  NA 
14  49  F  1998  +  1:4096  1:4096  2.6  271 
15  65  M  1998  –  1:256  1:1024  4.3  207 
16  26  M  1998  –  1:1024  NA  2.9  106 
17  44  F  1998  –  1:64  NA  10.0  397 
18  27  M  1998  –  1:64  NA  8.5  246 
19  24  F  1998  +  1:256  NA  2.4  69 
20  59  M  1998  –  1:1024  NA  4.9  102 
21  65  M  1998  –  1:256  NA  4.4  121 
22  52  M  1998  –  1:1024  1:1024  1.2  39 
23  54  M  1998  +  1:128  NA  NA  NA 
24  15  M  1997  –  Neg  1:64  6.4  308 
25  70  M  1997  +  Neg  NA  5.0  222 
26  47  F  1997  +  Neg  1:512  NA  NA 
27  31  M  1997  +  Neg  NA  3.5  56 
28  67  M  1997  –  1:2048  NA  5.2  208 
29  59  M  1997  –  1:4096  NA  6.9  166 
aSummary of all target genes used in the study: PCR, polymerase chain reaction; IFA, immunofluorescent assay; WBC, white blood cells; +, positive; –, negative; M, 
male; F, female; NA, not available. ranged from 2 to 8 weeks. In the acute-phase serum sam-
ples, nine patients (31%) had titers of <1:64, four (14%)
had titers between 1:64 and 1:128, seven (24%) had titers
between 1:256 and 1:512, and nine (31%) had titers
>1:1024. Of the convalescent samples, two (15%) had
titers between 1:64 and 1:128, five (39%) between 1:256
and 1:512, and six (46%) >1:1024. Cross-reactive antibod-
ies against A. phagocytophilum were found in nine cases
(31%), and all end-point titers were 1:160 or less. In all of
these cases, the IFA end-point titers against E. chaffeensis
were 1:512 or greater. 
Ehrlichial DNA was amplified by PCR in 15 of the 29
confirmed and probable cases and in 14 of the 25 con-
firmed cases (sensitivity: 52% and 56%, respectively). Of
the 14 HME patients who tested negative by PCR, 10
(71.4%) had IFAtiters >1:256 (eight of these case-patients
had titers >1:1024). Of the 15 cases diagnosed by PCR,
ehrlichial DNA was amplified in nine cases from one tar-
get gene, in four from two target genes and in two from all
three target genes used in the study. Twelve cases were
diagnosed by both PCR and IFA. No ehrlichial DNA was
amplified from acute-stage blood specimens of the 20
patients in the nonseroconversion control group (specifici-
ty >95%). PCR testing confirmed the infection in all but
one of the patients who seroconverted (sensitivity: 84%).
The positive likelihood ratio for PCR was theoretically
infinite since the specificity in our study was 100%.
However, because of the relatively small number of cases,
a specificity of >95% seems more adequate. In a hypothet-
ical situation of one false-positive PCR result in 100 tests
performed, the positive likelihood ratio would have been
56 and 84 for sensitivity values of 56% and 84%, respec-
tively. The negative likelihood ratio was 0.44 for a sensi-
tivity value of 56% and 0.16 for a value of 84%. The
posttest probabilities for a positive PCR test were 97% and
96% for sensitivity values of 84% and 56%, respectively.
The posttest probabilities of a negative PCR test were
4.3% and 11.1% for sensitivities of 84% and 56%, respec-
tively. Posttest probabilities were calculated on the basis of
the incidence of HME in the total population of the study
(102 patients), that is, patients who met the case definition
used in this study. 
DNA sequencing analysis of PCR products was per-
formed on samples from five patients that yielded PCR
products for the 16S rRNA, nadA and 120-kDa protein
genes. The sequences revealed greater than 99% homo-
logy with the published sequences of E. chaffeensis genes. 
Ehrlichia chaffeensis was not cultivated from any of the
blood samples that were shipped from Missouri to Texas. 
Twelve (41%) of the HME patients required hospital-
ization: eight men and four women. Differences in age and
laboratory data between hospitalized and nonhospitalized
patients were not statistically significant, except for the
degree of thrombocytopenia (Table 4). 
All patients in whom HME was diagnosed were treated
with doxycycline. Duration of treatment ranged from 2 to
4 weeks. Fever resolved within 24 hours in three patients
(19%), within 48 hours in 10 patients (62%), and within 72
hours in three patients (19%). 
Comparison of clinical parameters between HME case-
patients and the control group showed no statistically sig-
nificant differences between the two groups, except for the
presence of cough in the HME case-patient group, illus-
trating again the nonspecific clinical presentation of this
disease (Table 3). However, statistically significant differ-
ences between the two groups were observed for age,
WBC count, and absolute neutrophil count, but not for
platelet count, absolute lymphocyte count, or aspartate
aminotransferase levels (Table 3).
Discussion
HME is a prevalent disease in southeast Missouri, an
area similar to most of the rural southeastern United States
in terms of its white-tailed deer-lone star tick zoonotic
cycle of E. chaffeensis and exposure to the bite of infected
ticks. We enrolled 102 patients in the 3-year study, and 29
(28.4%) of patients had either definite or probable HME.
For 1997, 1998, and 1999, the calculated incidence for
HME was 2, 4.7, and 3 per 100,000 population, respect-
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Figure. Counties in southeastern Missouri and southwestern
Illinois in which cases of human monocytotropic ehrlichiosis (HME)
were diagnosed from 1997 to 1999. Numbers represent HME
cases in each county. Asingle case that occurred in Phelps County
(south-central Missouri) is not shown.ively (incidence calculations were based on the total pop-
ulation of all counties where the patients lived. Population
figures were obtained from the U.S. Census Bureau Web
site and are based on the 2000 U.S. Census (URL:
http://quickfacts.census.gov/qfd/states/29000.html). These
incidence figures are higher than expected, even for an
HME-endemic area such as Missouri. On the other hand,
HME has probably been underestimated throughout the
rural southeastern and south central states. In this particu-
lar disease-endemic area, our case-patients were identified
mainly in one primary care-based physician’s office that
cares for a population base of approximately 7,000 per-
sons. Therefore, the real incidence of HME is likely hig-
her in Cape Girardeau and surrounding counties than this
overall study dictated. Physicians who diligently pursue
the diagnosis are likely to be surprised by the frequency
with which cases are identified. In fact, Carpenter et al.
(21) reported a higher than expected incidence of HME in
a prospective study performed in central North Carolina,
an area well known for a high incidence of Rocky
Mountain spotted fever. 
Our clinical case definition was broad and tried to
include all potential cases of HME in the disease-endemic
area. Our laboratory criteria to diagnose HME in this study
are patterned after those of the Council of State and
Territorial Epidemiologists (CSTE), although our criteria
are even more stringent regarding PCR interpretation (24).
We required the amplification of ehrlichial DNA by two
primer sets or confirmation of PCR results by two differ-
ent laboratories. We also required positive serologic
assays, along with the PCR results, to confirm a suspected
case. Our aim was to avoid the inclusion of cases in which
PCR might have amplified ehrlichial DNA nonspecifi-
cally. However, our specificity for PCR testing was 100%. 
Our serologic criteria for laboratory diagnosis of HME
are the same as those proposed by CSTE. For confirmation
purposes, we considered end-point titers of 1:256 or
greater as a criterion when only one serum sample was
available for diagnosis. IFA seroconversion has been con-
sidered the standard criterion for the diagnosis of HME.
However, samples with high end-point titers by IFA
(>1:256) are highly suggestive of acute HME unless the
patient is recovering from an acute infection and the titers
are returning to normal levels. High end-point titers us-
ually return to lower levels several months after the patient
recovers clinically. In three of our case-patients, antibodies
against E. chaffeensis were still detectable 8 to10 months
after infection. In these cases, PCR or rising IFA titers
would help solve the diagnostic dilemma. Frequently,
diagnostic IFA end-point titers were lacking at the time of
the patient’s first visit. In this series, 31% of acute-phase
serum samples had a diagnostic titer. In addition, 45% of
the samples that tested positive (>1:64) at the initial visit
had titers <1:256. Therefore, convalescent-phase samples
are highly desirable to confirm cases of HME reliably.
Another important finding is the presence of cross-reacting
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Table 3. Comparison of selected clinical features and laboratory data between patients with human monocytotropic ehrlichiosis (HME) 
(case-patient group) and noncase group (control group). Cape Girardeau, Missouri, 1997–1999 
Clinical Feature  HME case-patient group N (%)  Control group N (%)  p value 
Fever  29 (100)  20 (100)  NA 
Headache  21 (72)  14 (70)  0.89
a 
Dizziness  6 (21)  2 (7)  0.44
b 
Myalgia/arthralgia  20 (69)  10 (50)  0.29
a 
Chills  13 (45)  7 (35)  0.69
a 
Weakness  11 (38)  3 (15)  0.15
a 
Nausea  11 (38)  3 (15)  0.13
a 
Vomiting  2 (7)  2 (10)  1.00
b 
Diarrhea  3 (10)  2 (10)  1.00
b 
Abdominal pain  2 (7)  1 (5)  1.00
b 
Cough  7 (24)  0 (0)  0.03
b 
Sore throat  6 (21)  0 (0)  0.07
b 
Rash  6 (21)  0 (0)  0.07
b 
Stiff neck  6 (21)  0 (0)  0.07
b 
Confusion  2 (7)  0 (0)  0.50
b 
Laboratory   Mean ±  SD/median  Mean ± SD/median  p value 
Age  48.6 ± 17.5  35.7 ± 19.9  0.02
c 
Leukocytes x 10
9 cells/L  4.67  6.25  0.04
d 
Neutrophils x 109 cells/L  2645  3810  0.03
d 
Lymphocytes x 10
9 cells/L  1677  1897  0.36
d 
Platelets x 10
9 cells/L  172± 101.8  250.8 ± 137.5  0.06
c 
Aspartate aminotransferase (U/L)  63  32  0.84
d 
aCalculated by using Fisher exact test.  
bCalculated by using chi-square test. 
cCalculated by using t-test. 
dCalculated by using Mann-Whitney rank sum test. 
 antibodies against A. phagocytophilum in 31% of our
patients. In these patients, the titers against E. chaffeensis
were higher than the titers against A. phagocytophilum,
and according to published criteria, these cases most
likely represent HME instead of A. phagocytophilum
infections (25). In addition, PCR testing did not detect A.
phagocytophilum DNA in any of the patients’ blood sam-
ples. The proportion of patients with cross-reacting anti-
bodies is higher than reported in other series, and at this
time we do not know the reason for this finding (6,26). 
E. ewingii infections likely occur in this patient popula-
tion as well. The specificity of the PCR primer sequences
ensure that none of the patients with infections diagnosed
by PCR amplification had E. ewingii infection. In addition,
we were able to test the 49 case-patients included in the
final analysis of the study retrospectively. After the first
reports of E. ewingii cases in humans in 1999, we retrieved
DNA from our freezers from those 49 case-patients. E.
ewingii–specific primers were used and no amplicons were
obtained. The possibility that a serum specimen that con-
tained antibodies stimulated by E. ewingii might have been
labeled as indicating HME cannot be excluded, owing to
cross-reactivity with E. chaffeensis. 
The sensitivity of PCR was calculated on the basis of
the total number of cases diagnosed by IFA. The relatively
low sensitivity (56%) in our study when compared to that
of Everett et al. (87%) and Standaert et al. (100%) is note-
worthy. We do not have a clear explanation for this differ-
ence. However, in those series all patients in whom
ehrlichial DNA was amplified from blood had low or neg-
ative IFA titers in the acute-phase serum sample, whereas
in our series a substantial number of patients had acute-
phase serum samples with high IFA end-point titers. This
difference suggests that the ehrlichemia might be lower in
cases where the immune response is well established. In
fact, a t-test analysis of the geometric mean titer of PCR-
positive versus PCR-negative persons yielded a statisti-
cally significant difference (p < <0.007), suggesting that
seropositive patients are less likely to be PCR-positive.
PCR sensitivity increased to 84% when only cases diag-
nosed by seroconversion were used to calculate it. The
specificity of PCR was 100%.The positive and negative
likelihood ratios and posttest probabilities based on sensi-
tivity and specificity suggest that PCR is a useful tool for
diagnosing HME in the early phase of the disease. 
Our failure to isolate E. chaffeensis from these cases is
most likely related to the delay in inoculating the blood
samples of patients with HME into cell culture. The inter-
val between blood sampling and inoculation may play a
critical role when attempts to obtain isolates of E. chaf-
feensis are made (22). 
The spectrum of illness in our study ranged from mild
to life-threatening disease that required hospitalization and
intensive care; 41% of the patients in our study were hos-
pitalized. Since we detected cases based on a clinical defi-
nition that included fever for >3 days, we probably ex-
cluded the mildest cases of the disease in which a self-lim-
ited illness developed, which resolved spontaneously. In
fact, asymptomatic seroconversion has been documented
in soldiers who underwent field training and were exposed
to ticks. However, whether the antigenic stimulation in
those cases was actually triggered by E. chaffeensis or by
some other antigenically related, less pathogenic bacteri-
um, such as E. ewingii or the unnamed white-tailed deer
Anaplasma species (both also associated with the lone star
tick) is not known (18,27). The clinical syndrome of HME
observed in this study is similar to that described in other
series (7,8,10,11,20–22) in that it can be a serious illness
that requires hospitalization in a large number of cases,
even though the prospective, clinic-based nature of the
study allowed more mild cases to be identified earlier in
the course of illness.
Comparison of the case-patient group and the control
group revealed the important difficulty in clinical diagno-
sis: few clinical symptoms differed between case-patients
and non–case-patients. Even the signs and symptoms that
showed some differences are nonspecific and can occur in
other clinical conditions. The relatively high frequency of
neurologic and respiratory signs is noteworthy, showing
the potential severity of this disease. Among the few
patients that underwent lumbar puncture in this study, the
CSF showed pleocytosis with lymphocytic predominance
(data not shown). Age, white blood cell counts, and
absolute neutrophil counts were statistically significantly
different between the HME and non-HME patients; throm-
bocytopenia was nearly statistically different (p = 0.06),
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Table 4. Association of selected demographic variables and laboratory data with severity of illness for 29 patients with human 
monocytotropic ehrlichiosis (HME), Cape Girardeau, Missouri, 1997–1999 
Parameter  Nonhospitalized mean ± SD/Median  Hospitalized mean ± SD/median  p value 
Age (y)  45.8 ± 17.5  51.8 ± 19.1  0.41 
Leukocyte count, x 10
9 L  5.1 ± 2.6  4.0 ± 1.7  0.21 
Platelets  192.4 ± 10
9  117 ± 66  0.05 
Neutrophil counts, x 10
9 
a  2,960  2,590  0.59 
Lymphocyte counts x 10
9 L  1,948.5 ± 112.7  1,383.4 ± 1,167.7  0.26 
Aspartate aminotransferase, U/L
a  89  49  0.96 
aDifferences analyzed by Mann-Whitney rank sum test. All others analyzed by t-test. pointing out again the importance of leukopenia and
thrombocytopenia as diagnostic clues during the acute
phase of the disease. The differences in age of the patients
confirm once again that HME tends to affect older people
more frequently than younger people (E. chaffeensis infec-
tion also may cause a milder illness in the young). 
In summary, HME is an emerging tick-borne disease;
its epidemiology and clinical spectrum are still being
determined, and the incidence is higher than previously
thought. The clinical diagnosis is challenging, and a high
degree of suspicion is required to order specific diagnostic
tests to confirm the diagnosis. PCR appears to be a useful
diagnostic test during the early phase of this potentially
life-threatening tick-borne zoonosis. 
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